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Summary at a glance  
Bronchiectasis in yellow nail syndrome (YNS) has distinct features which influence 
clinical presentation and management. Bronchiectasis in YNS is milder than in 
idiopathic bronchiectasis, with less upper and middle lobe disease, but increased mucus 
plugging. A better understanding of aetiology may influence future research and 
management decisions.  
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ABSTRACT 
Background and objective: Yellow nail syndrome (YNS) is a rare and poorly 
described disease process. In this case control study, clinical features and findings on 
high resolution computed tomography [HRCT] were compared with idiopathic 
bronchiectasis (IBx).   
Methods: A review of all patients attending an adult bronchiectasis clinic between 
2007 and 2013 identified 25 YNS patients. IBx patients were matched in a 2:1 ratio for 
age, duration of symptoms and gender.  
Results: Median age of onset was 53 years. There were 12 male and 23 Caucasian YNS 
patients. Respiratory manifestations included chronic productive cough (100%), 
chronic rhinosinusitis (88%), pleural effusions (20%), lymphoedema (12%). Chest 
symptoms preceded yellow nails in the majority (68%). Abnormal nails persisted at 
follow up in 23/25 patients but improved in 14. 
In both disorders, there was symmetrical, predominantly lower lobe bronchiectasis on 
HRCT. Extent (p=0.04), severity (p=0.03) and bronchial wall thickness (p=0.05) scores 
were lower in YNS, with less upper and middle lobe disease. Multivariate analysis 
showed an independent association with increased mucus plugging in YNS. There was 
a similar prevalence of Pseudomonas aeruginosa infection and mild lung function 
abnormalities. 
Conclusion: Bronchiectasis in YNS is less severe than IBx but is associated with 
increased mucus plugging, onset is in middle age and there is no female predominance. 
Treatment targeted at improved secretion clearance may improve both chest and nail 
symptoms, with consideration of longterm macrolide antibiotics. 
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INTRODUCTION 
 
Yellow Nail Syndrome (YNS) was initially described by Samman and White in 1964 
and the literature currently documents approximately 150 cases1. It is a rare clinical 
syndrome characterised by a triad of yellow dystrophic nails, lymphoedema, and 
pulmonary manifestations. These include chronic cough with sputum, recurrent 
respiratory infections, pleural effusions, bronchiectasis and rhinosinusitis. It has been 
previously accepted that two of the triad are adequate for diagnosis2. The complete triad 
occurs in one third of patients3 where symptoms may occur years apart4. The 
characteristic nail changes in YNS include yellow-green discolouration, slow growth, 
cross-ridging, loss of cuticle, over-curvature, onycholysis and shedding1.  
 
The aetiology of YNS remains undefined however the pathogenesis may involve 
impaired lymphatic drainage5. Lymphangiography has shown hypoplastic lymphatic 
systems in the legs and lungs of some patients1,5. This finding has not been confirmed 
by lymphoscintigraphic studies and, given the reversibility in some, the underlying 
cause may be functional rather than anatomical5. A small subset has hypoalbuminaemia 
caused by enteric albumin loss suggesting increased microvascular permeability6. The 
cause of bronchiectasis is unclear but may relate to dysfunctional lymphatics and 
impaired secretion drainage, with subsequent increased infection risk. 
 
In 2008 Maldonado et al described 41 patients with YNS, mean age of onset 61 years. 
18 patients (44%) had mainly symmetrical lower lobe bronchiectasis7. 17 (41%) had 
chronic rhinosinusitis. By comparison a study of 165 consecutive bronchiectasis 
patients referred to a single centre contained 4 patients with YNS and 43 with IBx. The 
 6 
mean age of onset of IBx was 43 years with female predominance (65%), with a 
predominantly lower lobe bronchiectasis and chronic rhinosinusitis8. 
 
Patients with different bronchiectasis aetiologies have characteristic CT scan 
appearances and clinical features. This case control study of patients referred to a 
tertiary speciality hospital aims to further define the respiratory features of YNS by 
comparing radiological findings, lung function and microbiology with a matched cohort 
of IBx patients.  
 
 
METHODS 
 
YNS patients were identified by electronically searching all Royal Brompton Hospital 
adult bronchiectasis clinic letters from 2007 to 2013. Patients were initially referred for 
chronic productive cough with suspected or previously confirmed bronchiectasis, with 
or without yellow nails. Diagnosis of YNS was made (often subsequently) after 
development of yellow nails. Clinical features, microbiology, radiology, lung function, 
progress and follow up duration were recorded. All patients had been investigated using 
a protocol previously published [8]. This includes blood investigations to exclude 
known aetiologies; nasal nitric oxide as a test for primary ciliary dyskinesia (followed 
by light and electron microscopy of nasal epithelium if indicated); sweat test (and/or 
genotyping) for cystic fibrosis8. The study was an anonymised retrospective review of 
cases and neither patient consent nor ethical approval was sought. All patients attending 
the Royal Brompton Hospital are informed about the use of patient data for continuing 
research at the hospital. 
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IBx patients were defined as having had no history of serious infections predating 
bronchiectasis, with normal or negative tests for other bronchiectasis aetiologies8. The 
IBx comparison group was formulated by matching IBx patients to YNS patients in a 
2:1 ratio, matched for age (within 10 years), duration of symptoms (within 5 years) and, 
for lung function comparison, gender.  
 
High resolution computed tomography (CT) scans were performed on initial 
assessment. 1.5 mm sections were obtained at 10 mm intervals, supine and at full 
inspiration. Bronchiectasis was defined according to accepted CT criteria9. All CT 
scans were independently reviewed by the same two experienced observers, blinded to 
clinical information. Observers awarded scores (grades) per lobe (lingula regarded as a 
separate lobe) for eight variables: extent of bronchiectasis, severity of bronchial 
dilation, bronchial wall thickness, mucus plugging, tree-in-bud pattern, mosaicism, 
consolidation and septal thickening. Full scoring criteria are described in 
Supplementary Appendix S1, and are similar to previous studies10-11. After initial 
scoring, a consensus score was agreed between observers in cases with >1 point 
discrepancy, where one result was zero, or where there was a >15% discrepancy for 
Mosaicism or Consolidation. Consensus scores were used for data analysis. 
 
Statistical  analysis 
HRCT variables were evaluated as follows: 
1. Global scores (per scan) for all variables were computed as the sum of lobar 
grades, with the exception of mosaic attenuation. See Appendix S1 for details 
of scoring system. For example, the maximum grade per lobe for “extent” 
was 3, therefore the maximum global extent score was 18 (assuming 6 lobes).  
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Global mosaic attenuation scores were calculated as the mean of lobar scores, 
as mosaic attenuation was a continuous variable rather than a grade 
(quantified as the percentage of total lung volume in each lobe).  Mean scores 
for the two observers were evaluated in all analyses of global variables. Lobar 
grades were recorded in a table as shown in Appendix S2, for each observer. 
2. Septal thickening and consolidation were seldom present and were not 
evaluated further.   
3. Regional scores were computed as upper lobe, middle lobe and lower lobe 
scores using the same approach as for global scores (i.e. mean lobar scores for 
mosaic attenuation, summed scores for all other variables). 
 
Group comparisons for all variables were made using the Wilcoxon rank sum test. A 
p value <0.05 indicated statistical significance.  Stepwise logistic regression was used 
to identify independent HRCT morphologic differences between YNS and IBx.  
 
Lung function was compared between diseases, where YNS and IBx patients were also 
sex matched (as well as for age and symptom duration). This meant that the matched 
IBx lung function group and radiology group were not necessarily formed of the same 
IBx patients. However, matched YNS/IBx patients were kept the same where possible; 
28 of the idiopathic patients used for lung function comparison were also used for CT 
comparison (this meant that there were 16 IBx patients that featured only in the PFT 
comparison group, and 10 that featured only in the CT comparison group). The YNS 
group was consistent throughout. The lung function matched IBx group was the 
comparator group used to compare microbiology findings between diseases (as opposed 
the IBx radiology matched group used for CT comparison). Lung function readings and 
 9 
microbiology data were recorded at initial assessment and at every subsequent visit (in 
order to record any subsequent P. aeruginosa infection). Lung function data were 
compared using an unpaired student t-test. Categorical variables, namely presence or 
absence of P. aeruginosa, were compared using a chi-squared test. P < 0.05 was 
regarded as being statistically significant.  
 
 
 
RESULTS 
 
Twenty five patients with YNS attended clinics at the Royal Brompton Hospital 
between 2007 and 2013. The median referral age of YNS was 58.2 years (range 11.8- 
77.7), and median age of first symptoms was 53 (range 4-75). 12 were male (48%). 
23/25 (92%) were Caucasian, from the UK and Ireland. One patient was from Iraq with 
Arabic origins, the other was Asian from Sri Lanka. All presented to the Royal 
Brompton with chronic cough and recurrent infections. During follow up, 21 patients 
suffered from chronic sinusitis, 10 had wheeze. Three patients had lymphoedema of 
lower limbs, one with left arm involvement. Five patients had a history of pleural 
effusion. Supplementary Tables S1 and S2 describe YNS and IBx individual patient 
characteristics in more detail. 
 
22/25 patients (88%) had abnormal nails at referral, with the remaining 3 patients 
developing yellow nails within two years. In the majority of patients (17, 68%), chest 
symptoms preceded nail changes. Yellow nails had preceded chest symptoms by one 
year in two patients, and occurred simultaneously in six. Two patients had a history of 
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malignancy (breast and melanoma), five patients had reflux, four had coronary artery 
disease and two had cardiac failure. One patient had asbestos plaques. The proportion 
of ex-smokers was similar between YNS and IBx (32% and 29% respectively). None 
were current smokers. 
 
Immunoglobulins were normal in all. Two patients had lymphopenia (lymphocyte 
count of 0.7 x109/L and 1.0x109/L). Four patients had low albumin levels of 26-34g/L. 
Seven patients had elevated IgE levels (>150 IU/mL). Two of these were diagnosed 
with aspergillus sensitivity, with Aspergillus fumigatus RAST results of 14.7 and 9.74 
IU/mL. Neither of these patients had peripheral eosinophilia nor clinical/radiological 
evidence of ABPA.  
 
The median follow-up was 6.2 years (range 0 to 19 years) in the YNS cohort, and 4.9 
years (range 0 to 14.7 years) in the IBx cohort. Zero follow up was recorded where 
patients were seen once only (1/25 YNS, 5/44 IBx). Initial referral dates ranged between 
1992-2013 for YNS, and 2001-2012 for IBx patients.  
 
Microbiology 
At initial referral, sputum cultured P. aeruginosa in 5/22 YNS patients (23%), 
Haemophilus influenzae in five (23%), Streptococcus pneumoniae in two (9%), and 
Moraxella catarrhalis in one patient (5%). Nine (41%) patients had no significant 
bacterial growth. 3 patients’ initial results were unavailable. No mycobacteria were 
cultured. By comparison, 12/44 (27%) IBx patients cultured P. aeruginosa. During 
follow up, 9 further YNS and 12 further IBx patients became colonised (64% and 55% 
of cohort respectively). There was no significant difference in incidence of P. 
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aeruginosa at presentation (p=0.69), or during follow up (p=0.48) between diseases. 
Table 1 compares microbiology between diseases. 
 
 
Lung function studies  
Lung function studies showed YNS to be a mildly obstructive lung disease, with no 
significant difference in readings compared to IBx (Table 2).  
 
Within the YNS group, patients colonised with P. aeruginosa at presentation had a 
statistically lower mean FEV1 (p=0.013) and FVC (p=0.042) than those without 
colonisation. 
 
Radiology  
Nineteen YNS patients had CT scans available, where seventeen showed 
bronchiectasis. The remaining two patients scored zero for extent and severity of 
bronchiectasis. However, both had bronchial wall thickening, chronic daily sputum 
production and recurrent infections, with bronchiectasis diagnosed clinically. One 
patient’s CT scan had been reported as mild bilateral lower lobe bronchiectasis by the 
radiologist reporting it originally; the second patient had right lower lobe bronchiectasis 
on a repeat scan 2 years later. 
YNS patients had significantly lower extent (p=0.04), severity (p=0.03) and bronchial 
wall thickness (p=0.05) scores than matched IBx patients, see Table 3. Differences in 
scores for tree in bud, mosaicism and mucus plugging did not reach statistical 
significance on initial analysis (Wilcoxons signed rank test). Consolidation was present 
in only 4/19 (21%) of YNS and 13/38 (34%) of IBx patients. Septal thickening was 
present in only 6/19 (32%) of YNS and 13/38 (34%) of IBx patients. Median global 
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scores for consolidation and septal thickening were zero, so they were not included in 
Table 3. 
 
Examination of a stepwise logistic regression model (with the HRCT variables listed in 
Table 3 examined as initial covariates prior to stepwise evaluation) showed that when 
compared to IBx, YNS was independently associated with less bronchial wall thickness 
(OR 0.64; 95% CI 0.46-0.87; p<0.005) and higher mucus plugging scores (OR 1.89; 
95% CI 1.10 – 3.25; p=0.02) than IBx. Analyses of the distribution of abnormalities on 
HRCT revealed that when compared to IBx, YNS was characterised by lower scores 
for the extent and severity of bronchiectasis and overall bronchial wall thickness (all 
p<0.05).  However, lower lobe scores taken in isolation did not differ between the two 
diseases for any HRCT variable.    Thus, compared to IBx, YNS is associated with 
sparing of the upper and middle lobes, with the abnormalities being present in the lower 
lobes.  
 
Management 
All patients received physiotherapy tuition at presentation and throughout follow up. 
Low dose antibiotic prophylaxis was introduced in 20 (80%) of YNS patients because 
of poor symptom control and/or four exacerbations or more per year. Three of these 
stopped antibiotics due to intolerance, side effects or non-response, leaving 17 on long-
term prophylaxis. Prophylaxis was oral azithromycin in 14/17 (82%) (usually 250mg 
three times weekly). This improved chest symptoms in the majority (9/14 =64%) of this 
group. One patient colonised with P. aeruginosa was taking colomycin nebulisers 
additionally as dual prophylaxis. 3/17 took other forms of antibiotic prophylaxis; 2 took 
colomycin alone (intolerant to azithromycin) with improvement in symptoms, and one 
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on regular erythromycin had no improvement. For the YNS group as a whole, 16 (64%) 
had a subjective improvement in chest symptoms since first review. Eleven of these 
were taking regular antibiotic prophylaxis and five patients improved with 
physiotherapy alone. Figures 1a and 1b shows a CT scan of a YNS patient before and 
after treatment with a long course of clarithromycin 250mg twice daily and inhaled 
colomycin 1million units twice daily, started when pseudomonas was isolated. 
 
23/25 patients had persisting nail changes at the time of last review, where 17 had 
improved over time. Seven of these also had improved chest symptoms over time. 
Resolution of nail changes occurred in two patients with improvement in chest 
symptoms (complete resolution in one). Figures 2a and 2b shows an example of one 
patient’s nail changes before and after treatment with physiotherapy and episodic 
antibiotics during infective exacerbations. 
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DISCUSSION 
This study investigates YNS patients referred to a tertiary hospital respiratory clinic, 
and compares them to matched IBx patients. IBx was chosen as the comparator group 
because both groups have normal or negative tests for other aetiologies, present in a 
similar way and are currently only differentiated by nail changes. A better 
understanding of aetiology may influence future research and management decisions. 
A recent multicentre study of 1258 bronchiectasis patients determined the aetiology in 
60%, where this knowledge changed the patient’s management in 13% of cases12. 
Additionally, the radiological and clinical findings in YNS bronchiectasis have been 
poorly defined. In Varney et al’s series of 17 YNS patients, all had chronic cough and 
the majority had rhinosinusitis (83%)13. Lymphoedema was present in 76%, compared 
to only 36% with lymphatic dysfunction in our series. Hoque et al. described eleven 
YNS patients of whom only six had bronchiectasis14. Comparable with our cohort the 
mean age of onset of symptoms was 53 years (range 27 to 69) but in contrast they 
reported lymphoedema in 46% of cases and only 27% had sinusitis. A recent study of 
165 consecutive bronchiectasis patients (43 with IBx) found the age average of onset 
of IBx was 43, 65% women8. Other studies have shown similarly younger age of onset 
for IBx and female predominance15-16. In our YNS cohort the average age of onset was 
53 years, with no gender predominance. 
 
YNS has been associated with other conditions including autoimmune disorders [4], 
immunodeficiency states17-18, nephrotic syndrome19, Guillain-Barre syndrome20, drugs 
(D-penicillamine, gold) and cancers4,6,17,19,21-28. Three of our patients had a history of 
malignancy. YNS has also been reportedly associated with lymphopenia, low IgA 
levels and hypogammaglobulinaemia29. Two patients in our series had lymphopenia but 
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immunoglobulin levels were normal in all. These previously described associations of 
YNS were therefore not seen in our cohort of patients presenting to a chest clinic. 
 
The notable CT finding of YNS in our study was symmetrical predominantly lower 
lobe bronchiectasis, with significantly less upper and middle lobe disease, and increased 
mucus plugging compared to IBx. Our cohort of YNS patients had significantly milder 
disease than IBx in terms of total extent, severity and bronchial wall thickening. 
However, this may be explained by disease being restricted to the lower lobes in YNS. 
We therefore hypothesise that bronchiectasis in YNS is a disorder of delayed 
mucociliary clearance due to abnormal lymphatic structure/function, where gravity 
influences lower lobe disease development. However, other factors such as frequency 
and severity of infections and the presence of other pro-inflammatory influences (such 
as aspergillus sensitivity in two patients), will also determine bronchiectasis 
development. Previous CT findings in YNS include one case series of four patients all 
with bronchiectasis primarily in the middle lobe, lingula and lower lobes30. Maldonado 
et al reported 41 YNS patients where 18 had bilateral lower lobe bronchiectasis on CT7. 
A possible explanation for milder disease in YNS could be earlier referral (and therefore 
treatment) due to yellow nail development. This explanation is however unlikely 
because YNS and IBx patients were matched by length of symptoms at the time of 
CT/lung function tests. 
 
The YNS group as a whole had mild abnormalities of lung function, although patients 
with P. aeruginosa had significantly poorer FEV1 readings at presentation (p=0.013). 
The association with P. aeruginosa with more severe airflow limitation has been noted 
in bronchiectasis previously31-32. Lung function was comparable to the IBx cohort, as 
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was incidence of P. aeruginosa both at presentation and subsequently. This was 
surprising considering less severe and less widespread bronchiectasis in YNS. One 
explanation could be increased mucus plugging predisposing to bacterial colonisation, 
or possibly higher use of antibiotic prophylaxis in this group. 
 
Longterm prophylaxis with azithromycin improved chest symptoms (cough, sputum 
and exacerbation frequency) in the majority (64%) of the YNS cohort taking it. This 
suggests that it is a good choice where symptom control is poor with physiotherapy and 
rescue antibiotics. Improvement with clarithromycin has been described in two case 
studies of YNS33-34. However, one study focussed on nail improvement, whilst the 
second described a case of eosinophilic bronchial disease in YNS, unlike in our cohort.  
 
There are some limitations to our study. YNS and IBx cohorts were matched for age 
and length of symptoms, therefore patient recollection was used to determine symptom 
onset date. The use of a small (five year) margin attempts to minimise poor recollection 
or individual variability in perception of symptoms. There may be some patient 
selection bias, as YNS patients may be referred earlier due to yellow nails rather than 
for problematic respiratory symptoms. However, the majority of YNS patients in our 
cohort were undiagnosed at referral. This study did not assess disease improvement 
objectively, and relied on clinic letter reports of symptoms. This is a small cohort of 
patients, as YNS is rare and we are a single centre. However, being a tertiary respiratory 
centre has enabled us to match IBx patients 
 
In conclusion, this study shows YNS as a distinct aetiology of bronchiectasis that may 
relate to impaired mucus clearance. The bronchiectasis in YNS is usually mild and 
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involves predominantly lower lobes, often presenting at an older age than IBx. 
Management should target mucus clearance. Longterm macrolide antibiotics may 
provide symptomatic relief, and in some cases led to resolution of dystrophic nails. 
Patients should be screened for impaired immunity, aspergillus sensitivity and 
malignancy, although these findings were uncommon in our cohort.   
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Table 1- Comparison of microbiology between diseases at first clinic appointment 
 
Initial Sputum culture 
results  
Yellow Nail Syndrome  
Frequency of culture 
result 
Idiopathic Bx frequency  
Frequency of culture 
result 
No growth/ Upper 
respiratory tract flora 
9 8 
Pseudomonas 
aeruginosa 
5 12 
Haemophilus 
Influenzae  
5 12 
Streptococcus 
pneumonia 
2 1 
Moraxella cattarhalis 1 4 
Stenotrophomonas 
maltophilia 
0 1 
Staphylococcus aureus 0 3 
Coliforms 0 1 
Serratia marcesens 0 1 
Beta haemolytic 
streptococcus 
0 1 
 Total samples =22  (3 
patients not available) 
Total samples = 44 
The IBx group used for comparison was the IBx lung function test group (patients 
varied very slightly to the IBx CT comparison group) 
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Table 2- Lung function tests in Yellow Nail Syndrome and Idiopathic Bronchiectasis 
 
Yellow Nail 
Syndrome 
n= 22  
Idiopathic 
bronchiectasis  
n= 44  
 
 
P value 
Mean FEV1 % of 
 predicted value 
(Standard deviation)  
 
 
83.86 (15.80) 
 
76.50 (26.91) 
 
0.251 
Mean FEV1/FVC ratio 
(Standard deviation) 
 
0.70 (0.10) 
 
0.67 (0.17) 
 
0.413  
Mean TLCO (transfer 
factor) % of predicted 
value 
(Standard deviation) 
 
76.43 (15.52) 
 
77.90 (16.70) 
 
0.740 
Student t test was used to compare data sets. 
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Table 3 High Resolution Computed Tomogram variables compared between Yellow 
Nail Syndrome and Idiopathic Bronchiectasis.  
 
HRCT variables including maximum scores are expressed as the sum of lobar scores 
for each patient, with the exception of mosaic attenuation (quantified as percentage of 
lung volume). All lobar scores were averaged for two observers, before summing. See 
Supplementary Appendix S1 for details of how each lobe was scored. 
 
HRCT variables 
 
(max score per 
scan) 
 
YNS -19 
patients 
Median CT 
score  
 
(range) 
 
IBx -38 patients 
Median CT 
score  
 
(range) 
 
 
P value 
Extent of 
bronchiectasis (18) 
4  
(0-14) 
8  
(0-16) 
0.04 
Severity of 
bronchiectasis  (24) 
5.5  
(0-13.5) 
8  
(0-18.5) 
0.03 
Wall thickness (24) 5.5  
(1-13) 
6.5 
 (1-17) 
0.05 
Tree in bud  (12) 2.5  
(0-7) 
2.75  
(0-8.5) 
0.73 
Mucus 
Plugging (12) 
2.0  
(0-6) 
2.0  
(0-8) 
0.80 
Mosaic attenuation 
(100%) 
20  
(0-65%) 
25  
(0-90%) 
0.86 
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Figure legends 
 
Figure 1- (A) 57 year old female with YNS at presentation. HRCT section through the 
lower lobes showing cylindrical bronchiectasis, particularly in the left lower lobe where 
there is an associated tree-in-bud pattern; there are also small foci of consolidation in 
the left lower lobe and lingual. (B)- In the same patient 18 months later, after treatment 
with a long course of clarithromycin 250mg twice daily and inhaled colomycin 1million 
units twice daily, The appearances in the left lower lobe have improved with resolution 
of the tree-in-bud pattern and consolidation. 
 
Figure 2 – (A) 54 year old man with yellow nails at first presentation, demonstrating 
discolouration, ridging and shedding. (B) - The same patient 1.5 years later 
demonstrating complete resolution of nail changes after treatment with physiotherapy 
alone. 
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